Bioassays of Humoral Cardioprotective Factors Released by Remote Ischemic Conditioning in Patients Undergoing Coronary Artery Bypass Surgery

Helmut Raphael Lieder, MD¹, Pia Tüller¹, Felix Braczko, MSc¹, Afsaneh Zandi, MD², Markus Kamler, MD²,³, Matthias Thielmann, MD³, Gerd Heusch, MD¹, and Petra Kleinbongard, MD, PhD¹

Abstract
Remote ischemic conditioning (RIC) induces the release of circulating cardioprotective factors and attenuates myocardial ischemia/reperfusion injury. Evidence for such humoral cardioprotective factor(s) is derived from transfer with plasma (derivatives) from one individual undergoing RIC to another individual’s heart, even across species. With transfer into an isolated perfused heart, only a single plasma (derivative) sample can be studied with infarct size as endpoint, and therefore the comparison of samples before and after RIC or between RIC and placebo is hampered by the inter-individual variation of infarct sizes in isolated perfused hearts. We therefore developed a preparation of cardiomyocytes from a single mouse heart, where aliquots of the same heart can undergo hypoxia/reoxygenation (H/R) with exposure to buffer, RIC, or placebo samples without or with pharmacological blockade. To validate this approach, we used plasma dialysates taken before and after RIC from patients undergoing coronary bypass grafting who had experienced protection by RIC (troponin release by 28% vs placebo). The cardiomyocyte bioassay had little variation after H/R with buffer (mean ± standard deviation; 7% ± 2% viable cells) and demonstrated preserved viability after RIC (15% ± 5% vs 6% ± 3% before). For comparison, infarct size in isolated mouse hearts after global ischemia and reperfusion was 22% ± 14% of left ventricular mass after versus 42% ± 14% before RIC. Statin, an inhibitor of signal transducer and activator of transcription (STAT)3 protein, abrogated protection in the cardiomyocytes. We have thus established a cardiomyocyte bioassay to analyze RIC’s protection which minimizes inter-individual variation and the use of animals.

Keywords
cardioprotection, ischemia/reperfusion, myocardial ischemia, remote ischemic conditioning, reperfusion injury

Introduction
Ischemic conditioning by brief cycles of coronary occlusion/reperfusion reduces not only infarct size in the dependent myocardium, but also at a distance in neighboring myocardium.¹ In fact, brief cycles of ischemia/reperfusion in a tissue or organ even further remote from the heart protect from myocardial ischemia/reperfusion injury.²,³ Remote ischemic conditioning (RIC) is a systemic phenomenon, which is elicited not only by ischemia/reperfusion but also by trauma and chemical or electrical sensory nerve stimulation. RIC is elicited from a variety of tissues and organs, and it also protects not only the heart but also a variety of other parenchymal organs.⁴,⁵ The signal transfer between the tissue of origin and the tissue of protection is through humoral and neuronal pathways which interact.⁵,⁶ RIC has been demonstrated in all species tested so far, including humans. A number of studies has evidenced cardioprotection in patients undergoing elective or primary interventional or surgical coronary revascularization,³,⁷ but not all studies were positive.⁸ In an individual patient undergoing a RIC protocol,

¹ Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany
² Heart Center Essen-Huttrop, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany
³ Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany

Manuscript submitted: March 09, 2022; accepted: April 10, 2022.

Corresponding Author:
Petra Kleinbongard, Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Hufelandstr 55, 45122 Essen, Germany.
Email: petra.kleinbongard@uk-essen.de
cardioprotection is difficult to assess. When measuring biomarkers such as troponin one does not know what the troponin release would have been without RIC. The same is true for imaging techniques which measure infarct size and have the advantage over biomarkers to provide also information on the area at risk.9

Evidence for humoral transfer of cardioprotective factors in RIC has been provided by transfer of plasma or plasma derivatives from one individual undergoing RIC to another individual’s heart preparation.10-14 However, when using an isolated perfused heart undergoing ischemia/reperfusion as a bioassay of cardioprotective transfer, only a single plasma/plasma derivative sample can be tested with infarct size as endpoint. Thus, the comparison of samples before and after RIC or of RIC versus placebo, respectively, entails inevitably the inter-individual variation inherent to infarct sizes in different isolated hearts which is considerable. We therefore developed a bioassay using isolated cardiomyocytes from a single mouse heart. Aliquots of cardiomyocytes can then be subjected in parallel to viability and buffer controls, exposure to RIC and placebo plasma/plasma derivatives without or with pharmacological blockade, thus avoiding inter-individual differences between different mouse hearts. More specifically, we compared the variation of bioassays using isolated perfused hearts undergoing ischemia/reperfusion with infarct size as endpoint and of isolated cardiomyocyte preparations from a single heart undergoing hypoxia/reoxygenation (H/R) with viability as endpoint. We evaluated the ability of the respective bioassay to detect the transfer of cardioprotective factors from a cohort of patients who underwent coronary bypass grafting and had protection by RIC as evidenced by reduced troponin release.15,16

Methods

Patient Cohort

The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the local Institutional Review Board of the University of Essen Medical School (#13-5507). Patients gave their written informed consent. Patients were recruited as part of an extended randomized placebo-controlled single center trial and underwent CABG surgery under isoflurane anesthesia (NCT01956708, date of registration: October 8, 2013). Inclusion and exclusion criteria have been reported previously.15,16 For the present analysis, samples from 40 consecutive patients who were enrolled between October 2014 and October 2015 were used. These patients underwent CABG surgery in a non-campus hospital and had less complex surgery than those in the entire cohort. RIC was induced by 3 cycles of 5 min right upper arm ischemia (by inflation of a blood pressure cuff to 200 mm Hg)/5 min reperfusion (by cuff deflation) after induction of general anesthesia and before skin incision. For placebo, the cuff was left deflated for 30 min. Venous blood samples were collected at baseline prior to RIC or placebo, and 30 min after completion of RIC or placebo, respectively. Additional venous blood samples were withdrawn at 1, 6, 12, 24, 48, and 72 h after surgery for the measurement of serum cardiac troponin T (cTnT). The cTnT area under the curve (AUC) calculated.15,16

Animals and Materials

All procedures involving animals were conducted in accordance with the German laws for animal welfare and the regulations of the local governmental Animal Care and Use Committee of the Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Germany, and are reported in accordance with the ARRIVE guidelines.17 The experimental protocols in isolated buffer-perfused mouse hearts and cardiomyocytes as well as the methods for the measurement of coronary flow (CF), left ventricular (LV) pressure and the quantification of infarct size and cardiomyocyte viability were standard9 and have been described in detail previously.13,18 Male C57Bl6/J mice, 20-27 g, 2.5 ± 0.5 months from Charles River (Sulzfeld, Germany, n = 177 in total) were used. Mice were housed in temperature- (23 °C ± 1 °C) and light-controlled (inverse 12:12 hour light-dark cycle) conditions. Food and water were provided ad libitum. Unless otherwise specified, materials were obtained from Sigma-Aldrich (Deisenhofen, Germany).

Plasma-Dialysate Preparation

Blood samples, collected before and after RIC or placebo, respectively, were centrifuged at 800 xg for 10 min to obtain plasma. The obtained plasma samples were again centrifuged at 2400 xg for 10 min before being placed into a dialysis tube with a pore size of 12-14 kDa (SpectraPor, Spectrum Europe, Breda, The Netherlands) and dialyzed against a 10-fold volume of saline buffer for 24 h using an orbital shaker. At least 6 mL of plasma was required to prepare a sufficient volume of plasma-dialysate for perfusion in the Langendorff apparatus. For the isolated perfused heart, a modified Krebs-Henseleit buffer18 was used (in mmol/L: NaCl 118.0, KCl 4.7, MgSO4 16.0, KH2PO4 1.2, glucose 5.6, sodium pyruvate 2.0), dialysate was titrated to CaCl2 2.0 and 24.0 NaHCO3, filtered with a 5 μm pore-sized syringe filter and gassed during prewarming to 37 °C with 95% O2 and 5% CO2, pH 7.40. For the isolated cardiomyocytes,13 1 mL plasma was dialyzed against a 10-fold volume of modified Tyrode buffer (containing in mmol/L: 125.0 NaCl, 5.4 KCl, 1.2 NaH2PO4, 20.0 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid, 5.0 taurine, 15.0 glucose, 2.5 creatine, 0.5 MgCl2) for 24 h using an orbital shaker. The dialysate was titrated to 1.0 CaCl2 and gassed with 100% oxygen, pH 7.4 before use. The plasma-dialysate from one patient in the placebo group was excluded from further experiments in isolated perfused mouse hearts, because precipitation of calcium and pH >7.9 occurred during the dialysis process, therefore two mouse hearts were not included in the analysis. Due to the limited volume of plasma samples, plasma-dialysates from only 13 patients with RIC and 11 patients with placebo were analyzed in the cardiomyocyte bioassay.
**Isolated Perfused Mouse Hearts**

Mice were sacrificed by cervical dislocation, their hearts isolated and perfused at constant pressure (80 mm Hg) with modified Krebs-Henseleit buffer. Heart rate was set to 500 beats/ min by right atrial pacing. CF was measured with an inline ultrasonic flowprobe (TS410, Transsonic Systems Inc., Ithaca, NY, USA) above the aortic cannula. A fluid-filled cine-film balloon was inserted into the LV cavity and connected to a pressure transducer (Codan-PVB, Lensahn, Germany) to measure LV pressure. End-diastolic LV pressure was set to 1-7 mm Hg at baseline by graded balloon inflation during the initial 5 min perfusion. Left ventricular developed pressure (LVDP) was calculated as the difference between peak and end-diastolic LV pressure. CF, end-diastolic and peak LV pressure were continuously recorded (LabChart 8, AD Instruments Pty LTD, New South Wales, Australia). Hearts were allowed to stabilize for 10-20 min. CF and LVDP were calculated as mean values during the last min each of the stabilization period (baseline), the last min of plasma-dialysate infusion, at 5 and 25 min ischemia and at 10, 30 and 60 min reperfusion, respectively. Preparations with CF <1.0 mL/min or >5.0 mL/min were discarded (n = 15) and divided into 5 aliquots each, respectively. Cardiomyocyte isolations with a viability of <60% at baseline were discarded (n = 7 preparations with viabilities ranging between 45% and 59%).

**Intra-individual variation of cardiomyocyte viability after H/R.**

Whereas the above experiments using patient plasma in isolated perfused heart and cardiomyocyte preparations were performed along with the patient recruitment, a separate series on the variation of viability in isolated cardiomyocyte preparations was performed in June and July 2021. Isolated cardiomyocytes from one single mouse heart were prepared as described above (n = 15) and divided into 5 aliquots each, respectively. Cardiomyocyte aliquots from one single heart were either incubated with buffer (n = 5 isolations, 750 µL buffer/ aliquot) or plasma-dialysate taken before or after RIC from patients (n = 5 isolations with 750 µL plasma-dialysate/ aliquot, each) for 30 min, respectively, and subjected to H/R. Hypoxia was induced for 50 min by exposing cardiomyocytes to glucose-free, non-gassed buffer (in mmol/L: 119.0 NaCl, 120.0 KCl, 5.0 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid, 0.5 MgCl2, 0.9 CaCl2, 20.0 sodium lactate, pH 6.5) and sealing with mineral oil. Cells were kept in solution at 20 °C where they sedimented. Reoxygenation was induced by removal of oil and glucose-free buffer and by adding reoxygenation buffer with an osmolality of 250 mosm/L (in mmol/L: 88.0 NaCl, 5.4 KCl, 1.2 NaH2PO4, 12.0 NaHCO3, 20.0 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid, 5.0 taurine, 2.5 creatine, 0.5 MgCl2, and 1.0 CaCl2, gassed with 100% oxygen, pH 7.4) for 5 min. In separate experiments (n = 4), the oxygen partial pressure during hypoxia was continuously measured using the oxygraph-2 k (O2 k, ORO-BOROS Instruments, Austria). The oxygen partial pressure at 1 min hypoxia was 66 ± 2 mm Hg and decreased within 10 min.

**Isolated Mouse Cardiomyocytes**

**Cardiomyocyte preparation.** Mice were sacrificed as described above, their hearts isolated and perfused with modified Tyrode buffer (in mmol/L: 113.0 NaCl, 4.7 KCl, 0.6 KH2PO4, 0.6, Na2HPO4, 1.2 MgSO4, 12.0 NaHCO3, 10.0 KHCO3, 10.0 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid, 30.0 taurine, 5.5 glucose, and 10.0 2,3-butanedione monoxime, pH 7.42 at 36.5 °C) at constant flow of 3 mL/min for 3 min. Liberase (Liberase TM Research Grade, Roche, Basel, Switzerland, 175 µg/ml), trypsin (75 µg/ml) and 12.5 µmol/L CaCl2 were subsequently added to the perfusion buffer, and hearts were digested for 4 min. Atrial and connective tissue was removed and discarded, ventricles were sectioned, and cells were re-suspended in Tyrode buffer containing 10% bovine calf serum (gibco, Thermo Fisher Scientific, Waltham, USA) and 12.5 µmol/L CaCl2. Cardiomyocytes were isolated, separated from tissue residues by filtering through a nylon mesh filter (200 µm pore size, Millipore, Billerica, USA), and CaCl2 was slowly titrated at 20 °C to a final concentration of 1 mmol/L (5 steps of 10 min duration each). Cardiomyocytes were kept in modified Tyrode buffer (containing in mmol/L: 125.0 NaCl, 5.4 KCl, 1.2 NaH2PO4, 20.0 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid, 5.0 taurine, 15.0 glucose, 2.5 creatine, 0.5 MgCl2, and 1.0 CaCl2, gassed with 100% oxygen, pH 7.4) at 20 °C under normoxic conditions for 5 min before viability was determined at baseline. Cardiomyocytes were stained with 0.5% trypan blue, and 300-700 cells per sample were analyzed in non-overlapping visual fields using light microscopy at 40 x magnification (Leica DMLB microscope, Leica, Bensheim, Germany). Viability was expressed as the percentage of rod-shaped, unstained cardiomyocytes over the total number of cells. Cardiomyocyte isolations with a viability of <60% at baseline were discarded (n = 7 preparations with viabilities ranging between 45% and 59%).

**Lieder et al**
Incubation with plasma-dialysates from individual patients. Cardiomyocyte aliquots from each isolation were either incubated for 30 min with RIC plasma-dialysate from blood taken before or after RIC, respectively, with plasma-dialysate from blood taken before or after placebo, respectively, or with modified Tyrode buffer (750 µL/aliquot) and subjected to H/R. Plasma samples from one individual patient were tested in cardiomyocytes isolated from one individual mouse heart. We have demonstrated in our previous study, that signal transducer and activator of transcription (STAT)3 activation in murine myocardium is causally involved in the cardioprotection transferred with human humoral factors released in response to RIC.18 Thus, all plasma-dialysates were incubated in the absence and presence of 1 µmol/L of the STAT3 blocker stattic (Tocris, Erkrath, Germany). The static concentration had been optimized in preliminary experiments to not impact on cardiomyocyte viability per se. In viability control (VC) experiments, cardiomyocytes were incubated for a duration equal to that of a H/R protocol i.e., 85 min. Modified Tyrode buffer was replaced with fresh oxygenated Tyrode buffer in VC experiments at the same time points when buffer was changed in H/R experiments, i.e., after 30 min and after 80 min of incubation. In separate experiments (n = 4) the oxygen partial pressure (oxygraph-2 k) was 152 ± 1 mm Hg after 30 min and decreased over the subsequent 50 min to 64 ± 1 mm Hg. Reoxygenation with modified Tyrode buffer restored oxygen partial pressure back to 163 ± 1 mm Hg. Cardiomyocyte samples were taken again at 85 min after H/R or VC, respectively, and viability was quantified. Plasma-dialysates before and after RIC, respectively, and before and after placebo, respectively, were used without or with stattic.

Statistical Analysis

Data are presented as means ± standard deviations. Experiments in isolated perfused mouse hearts and cardiomyocytes were performed using contemporary block randomization. Investigators performing experiments in isolated perfused mouse hearts and cardiomyocytes and analyzing infarct size, cardiomyocyte viability, and time courses of CF and LVDP in isolated hearts were blinded with respect to the nature of the plasma-dialysate (RIC/placebo and before/after, respectively). The Kolmogorov-Smirnov test was used to test for normal distribution of all data. Patient demographics and intraoperative characteristics were compared between RIC and placebo using unpaired Student’s t test (continuous data) or 2-tailed Fisher’s exact test (categorical data). The cTnT AUC was compared between RIC and placebo by unpaired Student’s t test. Two-way (time, group) ANOVA for repeated measures was used to analyze CF and LVDP in isolated perfused mouse hearts. Two-way (time, blocker) ANOVA for repeated measurements was used to analyze cardiomyocyte viability after incubation with plasma-dialysate and H/R. Fisher’s least-significant-difference post-hoc tests were used when the two-way ANOVA indicated a significant difference. One-way Kruskal-Wallis ANOVA on ranks was used to analyze infarct size in isolated perfused hearts. Individual mean values of data sets were compared by multiple comparisons procedures using Dunn’s method when ANOVA on ranks indicated a significant difference. Differences were considered significant at the level of P < .05 (SigmaStat 3.5, Erkrath, Germany).

Results

Patient Demographics and Perioperative cTnT AUC

Demographics and intra- and postoperative characteristics were not different between patients undergoing RIC and placebo, respectively (Table 1). The preoperative serum cTnT concentration did not differ between RIC and placebo. The cTnT AUC was reduced by 28% with RIC than with placebo (20.4 ± 9.0 versus 28.4 ± 14.0 ng/mL × 72 h, P = .0233), reflecting cardioprotection by RIC in this patient cohort.

CF, LVDP, and Infarct Size in Isolated Hearts

Baseline CF and LVDP of the isolated perfused mouse hearts were not different between TC, buffer, RIC and placebo and before and after RIC or placebo, respectively (Table 2). With infusion of plasma-dialysate after RIC, the recovery of LVDP at 10, 30 and 60 min reperfusion was better than with plasma-dialysate before RIC (Table 2). The recovery of CF during reperfusion was not different between isolated perfused mouse hearts with RIC and placebo and before and after RIC or placebo, respectively.

With VC, only negligible infarction (4% ± 2%) was detected (Figure 1). With buffer infusion and global ischaemia/reperfusion infarct size was 42% ± 9% (Figure 1). Infarct size was 42% ± 14% of ventricular mass with plasma-dialysate before RIC and significantly less (22% ± 14%) after infusion of plasma-dialysate after RIC (Figure 1). Infusion of plasma-dialysate taken before or after placebo, respectively, had no impact on infarct size (before placebo: 39% ± 14% versus after placebo: 40% ± 13%, Figure 1).

Cardiomyocyte Viability After H/R

The yield of viable cardiomyocytes over all cells ranged between 60% and 74% at baseline and was not different between isolations (Figures 2 and 3). The viability of cardiomyocyte aliquots from one single heart incubated with buffer
Discussion

We confirm the release of humoral cardioprotective factors from patients undergoing CABG surgery under isoflurane anesthesia with prior RIC which we have reported before.\textsuperscript{15,16} RIC’s cardioprotection was evidenced via reduction of postoperative troponin release in the cohort undergoing RIC as compared to the placebo cohort. Prior larger phase III trials, which did not report reduced troponin release in cardiac surgery patients with RIC,\textsuperscript{19,20} were confounded by use of propofol anesthesia\textsuperscript{21-23} which interferes with the protection by RIC.\textsuperscript{21-23} The less pronounced reduction of postoperative troponin in the present study may be attributed to less injury from shorter ischemic cross-clamp duration in this particular cohort when compared to the larger cohorts of our previous studies, which involved a greater proportion of more complex surgery.\textsuperscript{15,16} However, the focus of the present study was not on cardioprotection in patients per se, but on the release of circulating

| Table 1. Patient Demographics and Intraoperative Characteristics.\textsuperscript{a,b} |
|---------------------------------|---------------------------------|----------------|
|                                | RIC, n = 20                     | Placebo, n = 20 | P value |
| Demographics                   |                                |                |         |
| Age, years                     | 66 ± 11                        | 68 ± 9         | .57     |
| Sex, (male)                    | 14 (70%)                       | 16 (80%)       | .71     |
| Body weight, kg                | 80 ± 12                        | 82 ± 13        | .64     |
| Risk factors and comorbidities |                                |                |         |
| Chronic obstructive pulmonary disease | 2 (10%)                       | 0              | .48     |
| Diabetes mellitus              | 0 (0%)                         | 0 (0%)         | 1.00    |
| Hypertension                   | 17 (85%)                       | 15 (75%)       | .69     |
| Hypercholesterolemia           | 8 (40%)                        | 5 (25%)        | .50     |
| Peripheral arterial disease    | 1 (5%)                         | 1 (5%)         | 1.00    |
| Renal disease, creatinine >200 mol/L | 0                              | 0              | 1.00    |
| Cardiac status                 |                                |                |         |
| Angina CCS III to IV           | 10 (50%)                       | 15 (75%)       | .19     |
| Previous myocardial infarction | 2 (10%)                        | 2 (10%)        | 1.00    |
| Left ventricular ejection fraction, % | 46 ± 6                         | 48 ± 4         | .48     |
| Preoperative serum cTnT, ng/mL  | 0.01 ± 0.02                    | 0.01 ± 0.01    | .43     |
| Medication                     |                                |                |         |
| ACE inhibitors or ARBs         | 16 (80%)                       | 12 (60%)       | .30     |
| Aspirin                        | 20 (100%)                      | 19 (95%)       | 1.00    |
| ß-blockers                     | 16 (80%)                       | 15 (75%)       | 1.00    |
| Clopidogrel                     | 0                              | 2 (10%)        | .48     |
| Statins                        | 16 (80%)                       | 19 (95%)       | .34     |
| Risk scores                    |                                |                |         |
| EuroSCORE II, %                | 3 ± 2\textsuperscript{c}       | 2 ± 1          | .04     |
| Logistic EuroSCORE, %          | 4 ± 3\textsuperscript{c}       | 2 ± 1          | .013    |
| Intraoperative characteristics |                                |                |         |
| Aortic cross-clamp duration, min | 38 ± 14                        | 41 ± 11        | .42     |
| Cardioplegia, mL               | 1311 ± 210                     | 1342 ± 150     | .60     |
| Number of bypass grafts        | 3 ± 1                          | 3 ± 1          | .68     |
| Reperfusion time, min          | 22 ± 9                        | 27 ± 11        | .17     |
| Time from end of RIPC/placebo to cardioplegic arrest, min | 67 ± 22 | 75 ± 44 | .44 |
| Time from end of RIPC/placebo to reperfusion, min | 130 ± 32 | 150 ± 53 | .17 |

Abbreviations: ACE, angiotensin-converting enzyme; ARBs, angiotensin-II-receptor blockers; CCS, Canadian Cardiovascular Society; EuroSCORE, European system for cardiac operative risk evaluation; cTnT, cardiac troponin T; reperfusion time, time from the release of aortic cross-clamp to end of cardiopulmonary bypass; RIC, remote ischemic conditioning.

\textsuperscript{a}Data are means ± standard deviations or number (%).

\textsuperscript{b}Demographics and intraoperative characteristics were compared using Student’s t test (continuous data) or two-tailed Fisher’s exact test (categorical data).

\textsuperscript{c}P < .05 versus placebo; unpaired Student’s t test.

or plasma-dialysate before RIC before being subjected to H/R, was comparable and ranged between 5% to 9% with buffer and 2% to 8% with plasma-dialysate before RIC. Incubation with plasma dialysate after RIC preserved viability better (11%-21%) than incubation with plasma-dialysate before RIC or buffer (Figure 2). In experiments, where plasma-dialysates before/after RIC from individual patients were tested in cardiomyocytes isolated from one single heart, incubation with plasma-dialysate after RIC preserved viability after H/R better (15% ± 5%) than with plasma-dialysate before RIC (6% ± 3%). In VC experiments, cardiomyocyte viability significantly decreased by 9% ± 5% from a baseline of 66% ± 6%. Stattic per se had no impact on cardiomyocyte viability after H/R (Figure 3). Stattic abrogated the protection by plasma-dialysate after RIC (8% ± 3%) (Figure 3A). With plasma-dialysate before or after placebo, no protection was observed (before placebo: 8% ± 2% vs after placebo: 7% ± 3%, Figure 3B).
TC (n = 5), time corresponding to data points in the other protocols

---

| Time | CF (mL/min) | LVDP (mm Hg) |
|------|-------------|--------------|
| Baseline | 2.6 ± 1.4 | 71 ± 15 |
| +7 min | 2.7 ± 1.4 | 77 ± 11 |
| +25 min | 2.6 ± 1.5 | 81 ± 36 |
| +40 min | 2.6 ± 1.4 | 82 ± 34 |
| +50 min | 2.5 ± 1.4 | 70 ± 13 |
| +60 min | 2.6 ± 1.3 | 64 ± 13 |

Buffer (n = 24)

---

| Time | CF (mL/min) | LVDP (mm Hg) |
|------|-------------|--------------|
| Baseline | 3.0 ± 0.7 | 91 ± 16 |
| Buffer | 2.9 ± 0.7 | 89 ± 15 |
| Isch5 | 0 ± 0° | 0 ± 0° |
| Isch25 | 0 ± 0° | 0 ± 0° |
| Rep10 | 2.9 ± 1.6 | 15 ± 17° |
| Rep30 | 2.5 ± 1.3 | 27 ± 27° |
| Rep60 | 2.4 ± 1.2 | 31 ± 23° |

Plasma-dialysate before RIC (n = 20)

---

| Time | CF (mL/min) | LVDP (mm Hg) |
|------|-------------|--------------|
| Baseline | 2.6 ± 0.8 | 72 ± 19 |
| Dialysate | 2.9 ± 0.8 | 77 ± 25 |
| Isch5 | 0 ± 0° | 0 ± 1° |
| Isch25 | 0 ± 0° | 1 ± 1° |
| Rep10 | 2.8 ± 1.1 | 14 ± 21° |
| Rep30 | 2.5 ± 1.1 | 28 ± 21° |
| Rep60 | 2.4 ± 1.2 | 30 ± 18° |

Plasma-dialysate after RIC (n = 20)

---

| Time | CF (mL/min) | LVDP (mm Hg) |
|------|-------------|--------------|
| Baseline | 2.7 ± 0.6 | 82 ± 12 |
| Dialysate | 3.3 ± 0.8 | 95 ± 22 |
| Isch5 | 0 ± 0° | 1 ± 2° |
| Isch25 | 0 ± 0° | 1 ± 2° |
| Rep10 | 3.0 ± 1.0 | 26 ± 23°d |
| Rep30 | 2.9 ± 0.7 | 49 ± 21°d |
| Rep60 | 2.8 ± 0.7 | 54 ± 16°d |

Plasma-dialysate before placebo (n = 19)

---

| Time | CF (mL/min) | LVDP (mm Hg) |
|------|-------------|--------------|
| Baseline | 2.3 ± 0.5 | 79 ± 15 |
| Dialysate | 2.5 ± 0.5 | 88 ± 19 |
| Isch5 | 0 ± 0° | 1 ± 1° |
| Isch25 | 0 ± 0° | 0 ± 0° |
| Rep10 | 2.5 ± 0.6 | 28 ± 21° |
| Rep30 | 2.4 ± 0.6 | 53 ± 17° |
| Rep60 | 2.2 ± 0.6 | 51 ± 11° |

Plasma-dialysate after placebo (n = 19)

---

| Time | CF (mL/min) | LVDP (mm Hg) |
|------|-------------|--------------|
| Baseline | 2.8 ± 1.1 | 81 ± 21 |
| Dialysate | 3.0 ± 1.2 | 83 ± 20 |
| Isch5 | 0 ± 0° | 1 ± 1° |
| Isch25 | 0 ± 0° | 1 ± 1° |
| Rep10 | 2.8 ± 1.1 | 21 ± 25° |
| Rep30 | 2.7 ± 1.1 | 42 ± 26° |
| Rep60 | 2.6 ± 1.1 | 46 ± 26° |

**Table 2. CF and LVDP of Isolated Buffer-Perfused Mouse Hearts.**

| Abbreviations: Baseline, last min of stabilization period before ischemia/reperfusion; CF, coronary flow; isch5/25, 5/25 min of ischemia; LVDP, left ventricular developed pressure; n, number of mouse hearts; rep 10/30/60, 10/30/60 min reperfusion; RIC, remote ischemic conditioning. |
| Data are means ± standard deviations. |
| Basel values for CF and LVDP and their time courses were analyzed by two-way ANOVA for repeated measures and Fisher’s least significant difference post-hoc tests. |
| *P < .05 versus baseline, respectively. |
| **P < .05 versus before RIC.** |

The cardioprotective potential of plasma-dialysate from CABG surgery patients after RIC in the present study was comparable to that induced by plasma-dialysate from healthy...
In human myocardium, cardioprotection by RIC is associated with STAT5 activation, whereas the transfer of RIC’s cardioprotection with plasma-dialysate of healthy volunteers causally involves STAT3 activation in the myocardium of the isolated perfused mouse hearts. We now characterized RIC’s humoral transfer of protection more...
specifically as a cardiomyocyte phenomenon, associated with STAT3 activation in the isolated mouse cardiomyocytes. Whether or not our bioassay provides valuable information on cardioprotective factors of RIC not only in cardiosurgical patients, but also in patients with myocardial infarction undergoing remote ischemic perconditioning remains to be seen in future studies. For cardiosurgical patients, the cardiomyocyte approach may open new strategies to optimize cardioprotection on an individual basis.

Authors’ Note
The data generated during and/or analyzed in the current study are available from the corresponding author on reasonable request. Institution where the work reported was done: Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany.

Acknowledgments
Data of the present manuscript are scheduled to be part of P. Tüllers’ MD thesis.

Author Contributions
HL, PK, and GH designed the experiments. HL, PT, and FB performed the experiments and analyzed the data. AZ performed anesthesia and MK performed surgery in patients. MT collected and analyzed the patient data. HL and PK drafted the manuscript and GH interpreted the data and critically revised the manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GH and PK were supported by the German Research Foundation (SFB 1116, B08) and the EU COST ACTION in CARDIOPROTECTION (CA16225).

ORCID iD
Petra Kleinbongard https://orcid.org/0000-0003-3576-3772

References
1. Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic “preconditioning” protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993;87(3):893-899.
2. Heusch G. 25 years of remote ischemic conditioning: from laboratory curiosity to clinical outcome. Basic Res Cardiol. 2018;113(3):15.
3. Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17(12):773-789.
4. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon DM. Remote ischemic conditioning. J Am Coll Cardiol. 2015;65(2):177-195.
5. Kleinbongard P, Skyschally A, Heusch G. Cardioprotection by remote ischemic conditioning and its signal transduction. Pflügers Arch. 2017;469(2):159-181.
6. Pickard JM, Davidson SM, Hausenloy DJ, Yellon DM. Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. Basic Res Cardiol. 2016;111(4):50.
7. Heusch G, Rassaf T. Time to give up on cardioprotection? A critical appraisal of clinical studies on ischemic pre-, post-, and remote conditioning. Circ Res. 2016;119(5):676-695.
8. Heusch G, Gersh BJ. Is cardioprotection salvageable? Circulation. 2020;141(6):415-417.
9. Botker HE, Hausenloy D, Andreadou I, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018;113(5):39.
10. Shimizu M, Tropak M, Diaz RJ, et al. Transient limb ischaemia remotely preconditions through a humoral mechanism acting
directly on the myocardium: evidence suggesting cross-species protection. *Clin Sci (Lond)*. 2009;117(5):191-200.

11. Jensen RV, Stottrup NB, Kristiansen SB, Bøtcker HE. Release of a humoral circulating cardioprotective factor by remote ischemic preconditioning is dependent on preserved neural pathways in diabetic patients. *Basic Res Cardiol*. 2012;107(5):285.

12. skyschally A, Gent S, Amanakis G, et al. Across-species transfer of protection by remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. *Circ Res*. 2015;117(3):279-288.

13. Skyschally A, Kleinbongard P, Lieder HR, et al. Humoral transfer and intra-myocardial signal transduction of protection by remote ischemic preconditioning in pigs, rats, and mice. *Am J Physiol Heart Circ Physiol*. 2018;315(1):H159-H172.

14. Lieder HR, Kleinbongard P, Skyschally A, et al. Vago-splenic axis in signal transduction of remote ischemic preconditioning in pigs and rats. *Circ Res*. 2018;123(10):1152-1163.

15. Kleinbongard P, Gedik N, Kirca M, et al. Mitochondrial and contractile function of human right atrial tissue in response to remote ischemic conditioning. *J Am Heart Assoc*. 2018;7(15):e009540.

16. Thielmann M, Kottenberg E, Kleinbongard P, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. *Lancet*. 2013;382(9892):597-604.

17. Danos O, Davies K, Lehn P, Mulligan R. The ARRIVE guidelines, a welcome improvement to standards for reporting animal research. *J Mol Gen*. 2010;12(7):559-560.

18. Hildebrandt HA, Kreienkamp V, Gent S, et al. Kinetics and signal activation properties of circulating factor(s) from healthy volunteers undergoing remote ischemic pre-conditioning. *JACC Basic Transl Sci*. 2016;1(1):3-13.

19. Hausenloy DJ, Candilio L, Evans R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. *N Engl J Med*. 2015;373(15):1408-1417.

20. Meybohm P, Bein B, Brosteanu O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery. *N Engl J Med*. 2015;373(15):1397-1407.

21. Kottenberg E, Thielmann M, Bergmann L, et al. Protection by remote ischaemic preconditioning during coronary artery bypass grafting with isoflurane but not with propofol anesthesia—a clinical trial. *Acta Anaesthesiol Scand*. 2012;56(1):30-38.

22. Zangrillo A, Musu M, Greco T, et al. Additive effect on survival of anaesthetic cardiac protection and remote ischemic preconditioning in cardiac surgery: a Bayesian network meta-analysis of randomized trials. *PLoS One*. 2015;10(7):e0134264.

23. Heusch G, Gersh BJ. ERICCA and RIPHeart: two nails in the coffin for cardioprotection by remote ischemic conditioning? Probably not! *Eur Heart J*. 2016;37(2):200-202.

24. Kleinbongard P, Bøtcher HE, Ovize M, Hausenloy DJ, Heusch G. Co-morbidities and co-medications as confounders of cardioprotection—does it matter in the clinical setting? *Br J Pharmacol*. 2020;177(23):5252-5269.

25. Heusch G. Remote ischemic conditioning: the enigmatic transfer of protection. *Cardiovasc Res*. 2017;113(1):1-2.

26. Balls M. FRAME, animal experimentation and the three Rs: past, present and future. *Altern Lab Anim*. 2009;37(suppl 2):1-6.

27. Heusch G. Myocardial stunning and hibernation revisited. *Nat Rev Cardiol*. 2021;18(7):522-536.

28. Heusch G, Musiolik J, Kottenberg E, et al. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans. *Circ Res*. 2012;110(1):111-115.

29. Bøtcher HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. *Lancet*. 2010;375(9716):727-734.